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Abstract
Autoantibodies are infrequently detected in the sera of patients with the demyelinating form of Guillain-Barré
syndrome most commonly encountered in the Western world, despite abundant circumstantial evidence suggesting
their existence. We hypothesised that antibody specificities reliant on the cis interactions of neighbouring membrane
glycolipids could explain this discrepancy, and would not have been detected by traditional serological assays using
highly purified preparations of single gangliosides. To assess the frequency of glycolipid complex antibodies in a
Western European cohort of patients GBS we used a newly developed combinatorial glycoarray methodology to
screen against large range of antigens (11 gangliosides, 8 other single glycolipids and 162 heterodimeric glycolipid
complexes). Serum samples of 181 patients from a geographically defined, Western European cohort of GBS cases
were analysed, along with 161 control sera. Serum IgG binding to single gangliosides was observed in 80.0% of
axonal GBS cases, but in only 11.8% of cases with demyelinating electrophysiology. The inclusion of glycolipid
complexes increased the positivity rate in demyelinating disease to 62.4%. There were 40 antigens with statistically
significantly increased binding intensities in GBS as compared to healthy control sera. Of these, 7 complex antigens
and 1 single ganglioside also produced statistically significantly increased binding intensities in GBS versus
neurological disease controls. The detection of antibodies against specific complexes was associated with particular
clinical features including disease severity, requirement for mechanical ventilation, and axonal electrophysiology.
This study demonstrates that while antibodies against single gangliosides are often found in cases with axonal-type
electrophysiology, antibodies against glycolipid complexes predominate in cases with demyelinating
electrophysiology, providing a more robust serum biomarker than has ever been previously available for such cases.
This work confirms the activation of the humoral immune system in the dysimmune disease process in GBS, and
correlates patterns of antigen recognition with different clinical features.
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Introduction
Current evidence suggests that Guillain-Barré syndrome
(GBS) is caused in some cases by autoantibodies arising via
microbial molecular mimicry [1–4]. Certain antibodies clearly
correlate with particular disease subtypes [5] [6]; however,
these clinical-serological relationships are not absolute. GBS
cohorts dominated by demyelinating/AIDP-type
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electrophysiology have no prevalent antibody association, and
no serum biomarker is available to reliably support diagnosis
[7,8]. Furthermore, there are inconsistencies between the
ganglioside antigen tissue distribution and disease phenotype
[9], leading some to debate the pathological significance of
detected antibodies [10,11].
In addition to serological reactions with single ganglioside or
glycolipid species, it has recently been observed that certain
GBS-associated autoantibodies may only bind to ganglioside
complexes (GSC). GSC antibodies react with mixtures of two
different gangliosides, whilst failing to recognise either
component ganglioside alone, [12,13]. This concept builds on
the long standing hypotheses of a lectin-binding “clustered
saccharide patch” [14]. Following on from these serological
studies, the pathological importance of GM1-complex
antibodies [15,16] and the modulatory effects of GSCs on other
lectin-carbohydrate interactions [17,18] have both been
demonstrated. Nevertheless, the precise physico-chemical
nature of GSCs, and how they influence lectin and antibody
binding, still remains unknown. Although biophysical studies
show that cis (i.e. side-to-side) interactions between
neighbouring glycolipids in artificial and living membranes do
occur [19,20], the term ‘glycolipid complex’ is here used simply
to denote the mixture of two different glycolipids applied to a
membrane.
The relevance of GSC antibodies to Western GBS cohorts
dominated by demyelinating pattern electrophysiology, as
compared to Japanese cohorts with a greater proportion of
axonal GBS, is unexplored. Since screening serum samples for
anti-GSC reactivity is confounded by technical constraints, we
developed a combinatorial glycoarray whereby very small
quantities of glycolipid are sprayed onto polyvinylidene
difluoride (PVDF) membranes and then probed with serum
[17], allowing us to screen a large cohort of sera from GBS
patients against a large number of single and complex
glycolipid antigens. This approach enabled us to fulfil our aim
of delineating the glycolipid complex antibody profile in a
geographically defined cohort of Western European GBS
patients, providing a more robust serum biomarker than has
ever been previously available, and confirming the activation of
the humoral immune system in the disease.
Methods
Patient cohort
Patients and serum samples.  225 GBS patients were
recruited from centres across the Netherlands, Belgium and
Germany between 1994 and 2000 for a clinical trial [21].
Inclusion criteria were fulfilment of the NINDS diagnostic
criteria for GBS [7], GBS disability score of 3 or more (unable
to walk 10m unaided) [22], and onset of weakness within two
weeks before randomization. Ethical approval was obtained
from each centre in the Netherlands, Belgium and Germany
which participated in the original clinical trial, and informed
written consent was obtained from each individual patient. GBS
serum samples used were obtained within four weeks from
onset of weakness and before start of treatment. Only sera
from this one time point were available for analysis. For the
current study sufficient amounts of pre-treatment serum had to
be available for analysis. Serum samples from 74 healthy
controls (hospital and laboratory workers with no relevant past
medical history) and 87 patients with other neurological
diseases (“OND controls”, 40 with multiple sclerosis (MS), and
47 other ‘non-inflammatory’ neurological diseases – ONND,
collected as part of a previous study [23], see table S1 for
details) were also obtained. Sera were stored at -80°C and
defrosted shortly before each use.
Data collection.  Baseline characteristics and clinical
features were collected prospectively. Electrophysiological
examination was performed at one time point, and disease
classification based on accepted current criteria [24].
Serological screening had been previously performed for GM1,
GD1a and GQ1b ganglioside antibodies using a conventional
ELISA technique. By this assay a positive serum is defined by
an optical density for a ganglioside coated well more than 0.2
greater than uncoated control well, at a titre of 1:100 or greater
[25].
Combinatorial glycoarray
A TLC autosampler was used to apply glycolipid onto PVDF
membranes as previously described [26]. Glycolipids and their
sources, and the resulting GSC antigens created, are listed in
Table 1. LM1 and sulfated glucuronyl paragloboside (SGPG)
were extracted and purified as described [27,28]. Complexes
(1:1 by weight) were created by admixing equal volumes of the
component glycolipids. Arrays were blocked and then
incubated with sera diluted 1 in 100. After washing, rabbit anti-
human IgG horseradish peroxidase conjugated secondary
antibody (Dako) was applied at 1:30,000 dilution. The IgG
response alone was assessed as extensive previous
observations have indicated that IgG is the critical
immunoglobulin class in GBS. Binding was detected by
enhanced chemiluminescence (ECL+, Amersham/GE
Healthcare). Radiographs were digitised by flatbed scanning
and spot intensity calculated using TotalLab image analysis
software (Nonlinear Dynamics). The order of analysis of the
sera was determined by random number generation, the sera
coded, and the investigator performing image analysis blinded
to the identity of the serum applied to each membrane.
For practical purposes clinical samples were screened in
batches. Initially, GBS cases and healthy controls were
screened using an 11x11 and then 28x10 array (Table 1).
Antibody-antigen interactions statistically significantly
associated with GBS, in comparison with healthy controls, were
then re-evaluated with the inclusion of all 87 disease control
sera.
Statistical analysis
Initial analysis was performed using the Chi-squared test on
binary data (antigen binding present or absent) to investigate
overall antibody-antigen-disease associations. Intensity values
were used to produce heatmaps, which underwent iterative
clustering to reveal patterns of binding. Differences in binding
intensity between antigen groups (single gangliosides,
glycolipids and glycolipid complexes) were assessed by
Kruskal-Wallis with post-hoc analysis using the Mann-Whitney
Glycolipid Antibodies in Guillain-Barré Syndrome
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Table 1. Antigens included in the glycoarray.
1 SM* 46 PS:GM1+ 91 SGPG:GD3 136 GA1:Sulfatide+
2 PS*+ 47 PS:GD1a 92 SGPG:GQ1b 137 Sulfatide :GalC
3 Globoside*** 48 PS:GD1b+ 93 SGPG:GT1b 138 Sulfatide :GM1+
4 CTH*** 49 PS:GD3 94 SGPG:Sulfatide+ 139 Sulfatide :LM1
5 SGPG+ 50 PS:GQ1b 95 GM2:GM3 140 Sulfatide :GD3
6 GM2* 51 PS:GT1b 96 GM2:GD2 141 Sulfatide :GD1a
7 GM3* 52 PS:Sulfatide+ 97 GM2:GA1 142 Sulfatide :GD1b+
8 GD2* 53 Globoside:CTH 98 GM2:GalC 143 Sulfatide :GT1a
9 GA1* 54 Globoside:SGPG 99 GM2:LM1 144 Sulfatide :GT1b
10 GalC*** 55 Globoside:GM2 100 GM2:GM1 145 Sulfatide :GQ1b
11 LM1 56 Globoside:GM3 101 GM2:GD1a 146 GalC:GM1+
12 GM1*+ 57 Globoside:GD2 102 GM2:GD1b 147 GalC:LM1
13 GD1a* 58 Globoside:GA1 103 GM2:GD3 148 GalC:GD3
14 GD1b*+ 59 Globoside:GalC 104 GM2:GQ1b 149 GalC:GD1a
15 GD3* 60 Globoside:LM1 105 GM2:GT1b 150 GalC:GD1b
16 GQ1b** 61 Globoside:GM1 106 GM2:Sulfatide 151 GalC:GT1a
17 GT1b* 62 Globoside:GD1a 107 GM3:GD2 152 GalC:GT1b
18 Sulfatide* 63 Globoside:GD1b 108 GM3:GA1 153 GalC:GQ1b
19 GT1a*** 64 Globoside:GD3 109 GM3:GalC 154 GM1:LM1+
20 SM:PS 65 Globoside:GQ1b 110 GM3:LM1 155 GM1:GD3+
21 SM:Globoside 66 Globoside:GT1b 111 GM3:GM1+ 156 GM1:GD1a+
22 SM:CTH 67 Globoside:Sulfatide 112 GM3:GD1a 157 GM1:GD1b+
23 SM:SGPG 68 CTH :SGPG 113 GM3:GD1b+ 158 GM1:GT1a
24 SM:GM2 69 CTH :GM2 114 GM3:GD3 159 GM1:GT1b
25 SM:GM3 70 CTH :GM3 115 GM3:GQ1b 160 GM1:GQ1b
26 SM:GD2 71 CTH :GD2 116 GM3:GT1b 161 LM1:GD3
27 SM:GA1 72 CTH :GA1 117 GM3:Sulfatide 162 LM1:GD1a
28 SM:GalC 73 CTH :GalC 118 GD2:GA1+ 163 LM1:GD1b+
29 SM:LM1 74 CTH :LM1 119 GD2:GalC 164 LM1:GT1a
30 SM:GM1 75 CTH :GM1 120 GD2:LM1 165 LM1:GT1b
31 SM:GD1a 76 CTH :GD1a 121 GD2:GM1 166 LM1:GQ1b
32 SM:GD1b 77 CTH :GD1b 122 GD2:GD1a 167 GD3:GD1a
33 SM:GD3 78 CTH :GD3 123 GD2:GD1b 168 GD3:GD1b
34 SM:GQ1b 79 CTH :GQ1b 124 GD2:GD3 169 GD3:GT1a
35 SM:GT1b 80 CTH :GT1b 125 GD2:GQ1b 170 GD3:GT1b
36 SM:Sulfatide+ 81 CTH :Sulfatide+ 126 GD2:GT1b 171 GD3:GQ1b
37 PS:Globoside 82 SGPG:GM2 127 GD2:Sulfatide+ 172 GD1a:GD1b
38 PS:CTH 83 SGPG:GM3 128 GA1:GalC 173 GD1a:GT1a
39 PS:SGPG+ 84 SGPG:GD2 129 GA1:LM1+ 174 GD1a:GT1b
40 PS:GM2 85 SGPG:GA1 130 GA1:GM1+ 175 GD1a:GQ1b
41 PS:GM3 86 SGPG:GalC 131 GA1:GD1a+ 176 GD1b:GT1a
42 PS:GD2 87 SGPG:LM1 132 GA1:GD1b 177 GD1b:GT1b
43 PS:GA1+ 88 SGPG:GM1+ 133 GA1:GD3+ 178 GD1b:GQ1b
44 PS:GalC 89 SGPG:GD1a 134 GA1:GQ1b 179 GT1a:GT1b
45 PS:LM1 90 SGPG:GD1b+ 135 GA1:GT1b 180 GT1a:GQ1b
 181 GT1b:GQ1b
19 single glycolipids (numbers 1 to 19) and 172 1:1 complexes (20 to 181) were included in the assay in two separate screens. First an 11x11 array was performed,
comprising antigens numbered 10 to 19and the 45 1:1 heterodimeric complexes formed by these glycolipids. The remaining antigens were assessed on a 28x10 array. For
each spot 0.1µl per glycolipid (at 100µg/ml in methanol) was applied. Lipids were obtained from *Sigma, Poole, UK, **Accurate Chemical &Scientific, Westbury, USA, and
***Matreya, Pleasant Gap, USA. LM1 and SGPG were prepared and purified in house. +antigens with significantly increased binding frequency with GBS versus OND
control sera. Emboldened antigens had were significantly associated with GBS versus healthy controls following Bonferroni correction, italicised antigens were significant
only following less stringent Benjamini and Hochberg step-up correction for multiple comparisons.. (SM – sphingomyelin, PS – phosphatidylserine, GalC –
galactocerebroside, GA1 – asialo-GM1, sul – sulfatide, CTH – trihexosylceramide (ceramide trihexosides), SGPG - sulfated glucuronyl paragloboside)
doi: 10.1371/journal.pone.0082337.t001
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test. To compare the binding intensities achieved by GBS and
control sera to the multiple different individual antigens on the
array, raw intensity values were first logarithmically
transformed. A Mixed Model Analysis of Variance (ANOVA)
was then used to make multiple comparisons (in which zero
results were considered as the lowest value for a continuum of
binding intensities). This approach was also used to assess for
associations between clinical features and antigen binding
intensity, and allows for the fact that intensity values of some
antigens are likely to be inter-related. The problems associated
with analysing data with multiple zero values were addressed
by considering and comparing results obtained by the Chi-
squared and ANOVA and Mann-Whitney approaches. The
latter two methods were used after replacing zero intensity
values with a small positive value. Both Bonferroni and
Benjamini and Hochberg step-up correction techniques were
used to correct for multiple comparisons. The former is the
most conservative correction for multiple comparisons, but
therefore comes at the cost of a higher risk of false negatives.
As such, the less stringent and Benjamini and Hochberg step-
up technique was also used in certain exploratory situations.
Results
Patient cohort
Sufficient amounts of serum were available from 181 of 225
patients. Clinical data were available for 180 of these 181
patients. 103 were male (57.2%) and 77 female (42.8%). The
mean age of patients was 52.6 years (range 7 to 89). The
mean/median age was 44.2/44 for healthy controls, 55.7/56 for
OND controls, and 50.4/49 (range 25-83) for controls overall.
Electrophysiological data were available for 172 out of 181
patients. A single set of nerve conduction studies (NCS) was
performed at a median of 17 days (inter-quartile range 11-21
days) following the onset of weakness. According to the
Hadden criteria [24], the majority were classified either as AIDP
(85 cases, 49.4%) or equivocal (73 cases, 42.4%). Equivocal
patients had a definite clinical diagnosis of GBS, but in these
instances NCS were unable to distinguish demyelinating or
axonal subtypes following the single timepoint testing that
characterised the study design. Only 5 patients had
electrophysiology indicative of AMAN (Acute Motor Axonal
Neuropathy, 5.6% of characterised cases). Four cases had
normal neurophysiology and in 5 the nerves were unexcitable.
There were 5 deaths (2.8%) and 41 patients (22.8%) required
mechanical ventilation at some point.
Glycoarray Assay Performance
The inter- and intra-assay coefficients of variation (CV) for a
10x10 glycoarray had been previously calculated at 4.1% and
8.6% respectively, using an anti-GM1 monoclonal antibody
[17]. One positive GBS serum identified in the first screen of
the 28x10 assay was retested on 12 occasions over a 3 month
time period during the assessment of GBS and healthy control
samples. The inter-assay CV for this sample over this period,
involving multiple freeze-thaw cycles and different batches of
reagents, was 13.4%.
Initial Screening
Following initial screening using 11x11 and 28x10 arrays,
IgG antibodies in the sera of 113 GBS patients (62.4%) versus
11 controls (14.9%) bound to one or more antigens (p<0.001,
Chi-squared). GBS-associated sera displayed many different
binding patterns towards glycolipids and complexes (Figure
1A,B,D). No single antigen binding pattern was dominant.
Overall, GBS sera bound a wider range of antigens at higher
intensity compared to healthy controls (Figure 1C,D). Reactivity
towards 176 different single antigens and complexes was seen
with sera from GBS patients, whereas healthy control sera only
bound 31 of the 181 different antigens (p<0.0001, Binomial).
Figure S1 provides a detailed, zoomable version of this
heatmap showing binding patterns for each individual antigen
and serum. GBS patients testing positive were an average of
2.5 years older than those testing negative, whereas healthy
controls testing positive were an average of 2.2 years younger
than those testing negative. However, neither of these
differences reached statistical significance (p=0.375 and
p=0.589, independent samples T-test).
Low frequency and high specificity antibodies.  78
antigens were bound by IgG antibodies found in less than 10 of
the GBS sera and 22 antigens were recognised by only 1 or 2
sera. None of these 78 antigens were bound by IgG antibodies
in any of the 74 healthy control sera. Other GBS sera displayed
very restricted specificity - 13 sera showed binding against 1 or
2 antigens only (Figure 1B, further examples Figure S2A).
Additional GBS sera displayed more promiscuous binding to
multiple different antigens (Figure S2B)
Glycolipid complexes
Overall, complexes are bound at a significantly higher
median intensity compared to either single gangliosides or
glycolipids (Figure 1C, p<0.001, Kruskal-Wallis/Mann-Witney).
Furthermore, if binding to the 11 single gangliosides alone
were assessed by glycoarray, the positivity rate would be 80%
for AMAN cases, but only 11.8% for those with demyelinating
electrophysiology. In contrast, glycolipid complexes are bound
by IgG antibodies in 61.2% of sera from demyelinating cases.
Overall, the use of glycolipid complex binding intensity values
alone provides the best trade-off between sensitivity and
specificity for discriminating GBS from healthy control sera,
significantly outperforming single ganglioside and/or single
glycolipid results, as assessed by receiver operator curve
(ROC) analysis (p<0.0001 and p<0.001 respectively) (Figure
2A). Only the assessment of glycolipid complexes (AUC 0.758)
or the inclusion of all 181 antigens (AUC 0.756) resulted in a
test with an area under the curve (AUC) value in excess of
0.75, the accepted cut-off for a clinically useful test [29]. The
performance of these two antigen groups was insignificantly
different (p=0.33, ROC analysis).
In many cases the complex binding intensities produced by
GBS sera were greatly in excess of those seen towards the
component glycolipids of the complex assessed individually – a
phenomenon referred to as complex enhanced binding [18]
(example in Figure 2B,C). This pattern was much more
frequent (59.7% versus 13.5%, p<0.0001, Chi-squared) and
pronounced (median complex enhancement 5300 versus 0
Glycolipid Antibodies in Guillain-Barré Syndrome
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Figure 1.  Diverse patterns of glycolipid binding in GBS sera.  (A,B) Representative 28x10 arrays. The antigen spotted at each
grid location is revealed by combining the row and column headings given in the key below. Thus, locations (9,7) and (7,9) contain
GA1:GM3 complexes. The line of ‘x’ across the centre of the membrane represents the negative control spots (methanol only
spotted). The left most column and upper most row contain single antigens only.
(A) An array probed with GBS serum showing both complex attenuated and enhanced binding patterns. GD1b binding (14) is
completely attenuated in complex with GD2 (location 14,6). In contrast, despite no demonstrable binding to GA1, GM3 or GD1a in
isolation, an intense spot is seen with both GA1:GM3 (location 9,7) and GA1:GD1a (location 9,13) complexes. This is complex
enhanced/complex dependent binding.
(B) Highly specific complex-dependent GBS sera. In this example, only the duplicate spots of GM1:phosphatidylserine complex
(location 2,12) are bound.
(C) Boxplot of the distribution of maximum binding intensity for GBS versus healthy control (HC) sera assessed for single
gangliosides, single glycolipids, and glycolipid complexes. Maximum binding intensity is significantly higher for GBS sera versus
healthy control (HC) sera for each antigen group (*p<0.05, **p<0.0001). GBS sera maximum binding intensity for complexes is
significantly higher than for either single glycolipids or gangliosides (†=p<0.001), but HC sera maximum binding intensity is
insignificantly different between the antigen groups (not marked). (all Kruskal-Wallis/Mann-Whitney).
(D) Overview heatmap of raw, unclustered binding intensities for GBS (above horizontal white line) and HC (below horizontal white
line) sera. Antigens to the right of the vertical white line are glycolipid complexes. The intensity of binding is given by the bar above
the heatmap, ranging from black (negative) to red (most intense). A more detailed, zoomable version of this heatmap, allowing
resolution of results for each antigen and each serum, is available online (Figure S1).
Key: (1)Sphingomyelin, (2)Phosphatidylserine, (3)Globoside, (4)Cereamide trihexosides (CTH), (5) Sulfated glucuronyl
paragloboside (SGPG), (6)GM2, (7)GM3, (8)GD2, (9)Asialo-GM1, (10)Galactocerebroside (GalC), (11)LM1, (12)GM1, (13)GD1a,
(14)GD1b, (15)GD3, (16)GQ1b, (17)GT1b, (18)Sulfatide.
doi: 10.1371/journal.pone.0082337.g001
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Figure 2.  Complex enhanced binding.  (A) Receiver operator curves for single ganglioside antigens, single glycolipids, glycolipid
complexes, and for all 181 antigens. Complex antigens (dashed green line) afford the best trade-off between sensitivity and
specificity.
(B) Individual value plots for GBS sera binding intensity to single sulfatide (sul), single CTH, the sum of these single intensities
(sulfatide+CTH), and CTH:sulfatide complexes.
(C) Comparison between the sum of single sulfatide and CTH binding intensities (sul+CTH) and binding intensity to CTH:sulfatide
complexes in individual sera. Each line links the respective values in a single serum. Lines sloping upwards from left to right indicate
complex enhanced binding with a single serum.
(D) Overview heatmap of corrected complex binding intensities. The intensity value for each complex has been corrected by
subtracting the binding intensities of each component glycolipid. Any residual intensity indicates complex enhanced binding. As
before, GBS sera lie above and healthy control (HC) sera below the horizontal white line. The same colour scale as Figure 1 has
been used. A more detailed, zoomable version of this heatmap, allowing resolution of results for each complex antigen and each
serum, is available online (Figure S3).
doi: 10.1371/journal.pone.0082337.g002
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arbitrary units, p<0.0001, Mann-Whitney) with GBS versus
healthy control sera, as shown by the second heatmap (Figure
2D). This heatmap displays binding intensities for glycolipid
complexes following subtraction of single glycolipid binding
intensities (high resolution, zoomable version showing the
pattern of enhancement for each complex antigen and serum
available as Figure S3). Complex enhancement was
exclusively seen with GBS sera for 134 of the 161 complexes
tested.
Binding to a glycolipid complex without any detectable
binding whatsoever to the component glycolipids presented
individually has been termed ‘complex dependent’. Overall, 79
(43.6%) GBS sera showed this pattern, compared to only 3
(4.1%) of the healthy control sera (p<0.0001, Fisher’s Exact
Test). Examples were seen involving all of the glycolipids
assayed (Figure S2C).
Individual antigens with significantly increased binding
intensities
Logarithmic transformation of the intensity values, and
analysis by mixed effects model ANOVA with Bonferroni
correction, revealed 9 antigens with significantly increased
binding intensities in GBS as compared with healthy controls.
Seven of these were glycolipid complexes. Using the less
stringent Benjamini and Hochberg step-up correction for
multiple comparisons, a further 31 significant antigens (28
complexes) are returned (Table 1). The same technique was
used to identify specific antibody-antigen/intensity associations
for disease subtype (by electrophysiological criteria), disease
severity, identified preceding infection, cranial nerve
involvement, and the requirement for mechanical ventilation
(Table 2).
Antibody binding patterns in other neurological
disease control sera
The 40 antigens identified by intensity analysis as
significantly associated with GBS were then subjected to
testing with the 87 OND controls, alongside a randomly
selected subset of 20 anti-GSC antibody positive GBS sera.
Comparing the results of the retested GBS sera with those
from the original 28x10 assay, there were no significant
differences in positivity rates (using Fisher’s Exact test) or
average signal intensities (by Mann-Whitney) for 35 of the 40
antigens. All five of the discrepant antigens (sulfatide:GT1a,
LM1:GT1a, GM1:GT1a, GalC:GT1a, and SGPG:GalC) were
excluded from further analysis.
Hierarchical clustering using a Pearson’s Correlation metric
was used to uncover patterns of binding in GBS associated
sera, which was then compared to that seen in controls. This
revealed two major GBS binding clusters – one containing
sulfatide complexes and the other GM1 complexes (boxed in
Figure 3). Positivity in control cases mainly mapped to the
sulfatide cluster. Four sulfatide complexes cluster separately,
three of these (GM1:sulfatide, GD1b:sulfatide and
GA1:sulfatide, small arrows) are infrequently represented in
controls, Sulfatide:GalC (large arrow) binding is present in
OND controls at a frequency similar to other antigens in the
sulfatide cluster. Eight antigens displayed a significantly
increased binding intensity with GBS as compared to OND
control sera (Table 3), including GM1, 3 GM1 complexes, and
4 sulfatide complexes. The ROC/assay performance of this
subset of 8 antigens is insignificantly different to that of all 35
antigens together (p=0.32, Figure 4A).
Sulfatide and sulfatide series complex antibodies
Sulfatide-complex antibodies form the largest group of
antibodies found to be statistically associated with GBS.
Sulfatide as a single glycolipid is bound at relatively low
intensity by IgG in GBS sera, there is some overlap with
healthy control binding intensity, and no significant difference in
binding as compared to OND control sera. Once again
however, disease binding intensity and separation from control
cases is substantially improved with certain sulfatide
complexes, such asialo-GM1:sulfatide and CTH:sulfatide
(Figure 4B). Furthermore, there is a differential relative
response to single sulfatide and sulfatide-complex antigens
between GBS and control sera. Overall, GBS sera show a
more frequent and more pronounced complex-enhanced
response to these sulfatide-containing complexes than do OND
or healthy control sera (Kruskal-Wallis test for degree of
complex enhancement, CTH:sul p=0.025, GA1:sul p=0.037,
both p<0.001 when corrected for ties, Chi-squared comparison
of frequency of complex enhancement, p<0.0001 for both
antigens) (Figure 4C).
Table 2. Clinical features significantly associated with
specific antigens.
Clinical Feature Significantly associated antigens
Axonal Electrophysiology
CTH :GM1, GD2:GM1, Globoside:GM1,
GalC:GM1, GA1:GM1, GM1, GM1:GD1b,
SM:GM1, GM3:GM1, GM1:GD3, SGPG:GM1,
GM2:GM1, PS:GM1, Sulfatide:GM1, GA1:GalC,
GM1:GQ1b, GA1, GA1:Sulfatide
Greater Disease Severity
CTH :GA1*, Globoside:GA1*, PS:GalC,
GA1:GalC, Globoside:GD3, GD2:GD3, GA1,
GD3:GT1b, GalC:GQ1b
Preceding Campylobacter
jejuni infection
GD1a:GT1b, GD3:GD1a, Sulfatide:GD1a,
GalC:GD1a, GM2:GD1a, GD1a, GD1a:GQ1b,
GD2:GD1a, CTH:GD1a
No cranial nerve deficit Sulfatide:GM1, Sulfatide:GT1a
Following Bonferroni correction, 18 antigens (including GM1 and 14 GM1
containing complexes) were significantly positively associated with the AMAN
variant of GBS, as compared with neurophysiologically confirmed AIDP.
Nine antigens were statistically significantly positively associated with severe
disease (GBS disability score >3), but only at the point of randomisation (day 0). At
other assessed time points, this association is not seen. Antigens marked with an
asterisk were also significantly independently associated with the requirement for
mechanical ventilation.
Antigen-antibody associations with preceding Campylobacter jejuni infection
comprise solely of GD1a and GD1a series complexes.
(SM – sphingomyelin, PS – phosphatidylserine, GalC – galactocerebroside, GA1 –
asialo-GM1)
doi: 10.1371/journal.pone.0082337.t002
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Figure 3.  Heatmap of glycolipid complex binding in GBS and control sera.  Clustered heatmap for the 35 antigens significantly
associated with GBS (arranged on the x-axis), comparing the 181 GBS sera and 161 control sera (on the y-axis). Each row
represents a single serum. The log transformed arbitrary binding intensity for each antigen is represented by the colour scale, from
red (log transformed arbitrary intensity of 18, most intense) to the green background (log transformed arbitrary intensity of 0, no
binding), as shown at the top of the figure. Each heatmap panel represents a separate group, as labelled. (GBS, Guillain-Barré
syndrome; MS, Multiple Sclerosis; ONND, Other Non-Inflammatory Neurological Diseases; HC, Healthy Controls). Blue boxes
delineate clusters of GM1 and sulfatide-complex antigens. Arrows mark sulfatide complexes which cluster separately.
doi: 10.1371/journal.pone.0082337.g003
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GM1 and GM1 series complex antibodies
In contrast to sulfatide, binding to single GM1 is significantly
increased in GBS compared to OND control sera (Table 3).
Even so, GM1 complexes have greater sensitivity and
increased binding intensity over GM1 alone, without a
significant loss of specificity (Figure 5A). Analysis of relative
binding intensities in single patients reveals that both PS:GM1
and sulfatide :GM1 complexes are often bound by sera from
patients entirely negative for GM1 reactivity (Figure 5B,C). The
reverse also occurs, but is less often seen. Furthermore,
investigating the association between PS:GM1 and
sulfatide:GM1 binding intensity in individual sera uncovers at
least three different populations of GM1-complex antibodies –
those which preferentially (or indeed exclusively) bind one
complex, and those which bind both relatively equally (Figure
5D).
Comparison with ELISA
Just 39 of the 180 (21.7%) GBS sera had been positive
when tested contemporaneously using a conventional GM1,
GD1a, and GQ1b ELISA [25]. For these three ganglioside
antigens alone, the array detected binding in only 27 cases,
and was negative for 15 of the sera which had been positive on
ELISA. Only 9 of 85 cases (10.6%) with demyelinating pattern
electrophysiology were positive by ELISA (versus 62.4% for
binding to all antigens on the array), compared to 4 of the 5
AMAN patients (80%, identical to the array). The remainder of
Table 3. Antigens with significantly increased binding
intensities for GBS versus OND sera.
Antigen
Corrected
(Bonferroni) (p
value) Sensitivity   Specificity   AUC
Phosphatidylserine:Sulfatide* 0.00018 37% 90.7% 0.631
CTH:Sulfatide* 0.00092 27.1% 96.3% 0.617
Phosphatidylserine:GM1 0.0024 14.4% 100% 0.575
Phosphatidylserine:SGPG* 0.0050 28.7% 95% 0.615
SGPG:GM1 0.0056 13.3% 100% 0.566
Sulfatide:GM1 0.0077 13.8% 99.4% 0.566
GM1 0.024 11% 100% 0.555
GA1:Sulfatide* 0.034 17.7% 98.8% 0.583
(Above 8 Antigens Overall)  (55.2%) (85.7%) (0.716)
The eight antigens above had significantly increased GBS sera binding intensities
versus OND controls, following Bonferroni correction, and all also had significantly
increased positivity rates (corrected p value <0.05). Antigens marked with an
asterisk also showed significantly increased binding intensities versus normal
controls following Bonferroni correction. All of the antigens listed also had
significantly increased binding intensities versus healthy controls following the less
stringent step-up correction. The sensitivity and specificity values given are based
on a cut value of zero (i.e. a binding intensity value greater than zero is considered
positive).
(GA1 – asialo-GM1, CTH – trihexosylceramide (ceramide trihexosides), SGPG -
sulfated glucuronyl paragloboside, AUC = area under curve, from Receiver
Operator Curve analysis)
doi: 10.1371/journal.pone.0082337.t003
ELISA positive cases had either equivocal (24 patients) or
unavailable (2 patients) electrophysiology results. Only one
GBS serum which was positive by ELISA was entirely negative
by glycoarray.
Discussion
The combinatorial glycoarray technique has substantially
increased the number of glycolipid antibody specificities
significantly associated with GBS. Glycolipid complexes are
important both for the overall detection rate and for revealing
differences in the fine antibody specificities of disease versus
control sera. Although antibodies against single gangliosides
are frequently found in axonal disease subtypes, glycolipid-
complex antigens are more important for increasing the
positivity rate in cases labelled as AIDP or ‘equivocal’ by the
electrophysiological methods in use at the time of the clinical
study.
Rather than identifying a single specificity, however, the
antibody response in GBS is shown to be diverse and includes
extensive complex enhanced binding. Whether this reflects
some aspect of the underlying dysimmune process in GBS is
unclear. It is interesting to speculate that a change in antibody
specificity from a single to complex response is a key part of
the immune-pathological process. Even without any assertion
of pathogenesis, however, it is apparent that there is a
generalised upregulation in the glycolipid complex IgG
response in GBS. This does not appear simply to be a function
of increasing age. In contrast to traditional models of humorally
mediated pathology invoking a single antigen target for each
disease, the response in GBS has a highly variable fine
specificity towards many different neuronal and myelin
glycolipid complexes, and there is evidence from this study that
this correlates with the variable clinical presentation. That an
additional, dominant, antibody specificity has thus far escaped
detection is perhaps less likely.
Until recently, Western GBS has been considered to be
predominantly AIDP. New observations dependent upon serial
electrophysiological studies now suggest that a proportion of
cases labelled as AIDP (or equivocal) by a single study may
instead have axonal pathology [30]. Serial nerve conduction
studies are not routine, and the true proportions of
demyelinating and axonal subtypes in different geographical
populations is therefore unknown. Nevertheless, even amongst
the small number of axonal cases in our series, GM1 and GM1
complexes were bound at significantly greater intensity, and
single gangliosides at significantly increased frequency, as
compared to cases with a demyelinating and/or equivocal
electrophysiological categorisation. This is consistent with the
previously reported clinical-serological correlations for the
axonal disease subtype [31].This GBS cohort was
geographically defined and is representative of the local mix of
GBS subtypes. As such, overall positivity rates will be reflective
of those in GBS cases in this region, regardless of the true
proportion of pathologically axonal or demyelinating cases.
Care needs to be taken in correlating patterns of antibody
reactivity with pathological subtypes when only a single
neurophysiological study has been performed. Likewise, the
Glycolipid Antibodies in Guillain-Barré Syndrome
PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e82337
Figure 4.  Differing patterns of sulfatide complex enhanced binding in disease versus control sera.  (A) The receiver
operator curve for the 8 antigen intensities significantly associated with GBS versus OND controls is insignificantly different to that
produced by including all 35 antigens.
(B) Individual value plots of binding intensity for GBS, healthy control (HC), and other neurological disease (OND) sera to sulfatide,
CTH:sulfatifde complex, and GA1:sulfatide complex.
(C) Mean change in complex compared to summed single antigen binding intensity for CTH:sulfatide and GA1:sulfatide. On
average, GBS sera show complex enhancement, whereas HC and OND sera show complex attenuation.
doi: 10.1371/journal.pone.0082337.g004
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discrepancy between ELISA and glycoarray results highlights
the way in which different surfaces can alter antibody binding
patterns to glycolipids, possibly through differences in antigen
conformation and accessibility, raising the possibility that
antibody-glycolipid interactions in live membranes may be
different still.
The pathogenic potential of complex antibodies remains
speculative and incompletely proven. Ex vivo studies on murine
neuromuscular tissue have revealed that some GM1:GD1a
complex antibodies from AMAN cases bind, activate
complement, and pathologically effect neurophysiological
function of axon terminals within the neuromuscular junction
[16]. Whether the larger population of anti-glycolipid complex
antibodies described herein have such an effect, or
alternatively result in complement mediated damage at sites
within the node of Ranvier or to compact myelin [32], remains
to be seen. Even in diseases traditionally thought to be ‘non-
inflammatory’, glycolipid complex antibodies are detected at an
increased frequency compared to healthy controls, albeit at
lower binding intensities than in GBS. Binding to single
sulfatide is widely seen in many disease states, perhaps
reflecting non-specific antibody interactions with the sulfated
headgroup, whereas antibodies binding certain sulfatide
complexes are specifically associated with GBS. The
importance of these complex antibodies for GBS and other
diseases is unclear. They may be epiphenomena arising as a
by-product of antigen release in tissue damage or represent a
non-specific up-regulation of humoral immunity in post-
infectious states. In this GBS cohort, only single serum
samples collected early in the disease course were available
for analysis. Therefore, from this study the temporal
relationship between the detected antibodies and the disease
cannot be firmly established. Larger cohort studies collecting
longitudinal data are required to address this, and are on-going
[33]. Distinguishing the nature and pathological effects of the
disease relevant antibody component from polyclonal
background in sera is also problematic, and will require the
development of anti-complex monoclonal antibodies.
Figure 5.  GM1 complex antigens.  (A) Individual value plots for selected antigens.
(B) Association between sulfatide:GM1 and GM1 binding intensities in individual sera. Points on the y-axis are GM1 negative,
sulfatide:GM1 positive. Sera close to the diagonal blue line (joining points of identical binding intensity for both antigens) bind both
GM1 and sulfatide:GM1 complex with similar intensity.
(C) Association between phosphatidylserine:GM1 and GM1 binding intensities in individual sera. Points on the y-axis are GM1
negative, PS:GM1 positive. Sera on the x-axis are GM1 positive, PS:GM1 negative.
(D) Association between phosphatidylserine:GM1 and sulfatide:GM1 binding intensities in individual sera.
doi: 10.1371/journal.pone.0082337.g005
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Very limited information is available on the existence or
distribution of glycolipid complexes in vivo, although when
identified they are known to have profound effects on antibody
binding [15]. It is likely that a range of complexes exist in
different anatomical locations, but this remains to be
demonstrated. Their presence could explain many unresolved
enigmas in GBS.
The technology described here can readily be applied to
other areas of humoral immunity and autoimmunity in which
lipids and glycolipids are targets, and enables rapid screening
against a large range of glycolipid antigens. A general re-
examination of research in the area of anti-lipid/glycolipid
antibodies is required, taking into account the additional
considerations introduced by complexes. Such approaches
may allow the detection of other, previously elusive,
autoantibodies.
Supporting Information
Figure S1.  High resolution unsorted heatmap of binding
intensities. .GBS patients (above horizontal white line) and
healthy controls (below horizontal white line) are compared.
Antigens are listed on the x-axis such that each column of the
heatmap represents the range of binding seen for that antigen.
Each row represents the range and intensity of antigen binding
seen in an individual patient/serum. The intensity of binding is
given by the bar above the heatmap, ranging from black
(negative) to red (most intense).
(TIF)
Figure S2.  Glycolipid complex binding patterns of GBS
sera. Both highly specific (A) and promiscuous (B) binding
were seen with different GBS patient sera. Many sera showed
absolute complex dependent binding. In these cases, sera
bound a heterodimeric 1:1 complex without any detectable
binding to either component glycolipid presented individually.
This phenomenon was observed 828 times (as some sera
demonstrated multiple examples). Most often,
phosphatidylserine (pulled out slice) was the partnering
glycolipid in this situation, but examples were seen involving all
of the glycolipids assayed (C).
(DOCX)
Figure S3.  Overview heatmap of corrected complex
binding intensities. The intensity value for each complex has
been corrected by subtracting the binding intensities of each
component glycolipid. Any residual intensity indicates complex
enhanced binding. As before, GBS sera lie above and healthy
control (HC) sera below the horizontal white line. The same
colour scale as Figure S1 has been used.
(TIF)
Table S1.  Diagnoses of patients with other neurological
diseases used as controls. ONND – other non-inflammatory
neurological diseases, MS – multiple sclerosis, RR – relapsing
remitting, PP – primary progressive, SP – secondary
progressive, CIS – clinically isolated syndrome, TM –
transverse myelitis, CFS – chronic fatigue syndrome, IIH –
idiopathic intracranial hypertension, CVD – cerebrovascular
disease, PFO – patent foramen ovale, CVST – cerebral venous
sinus thrombosis.
(DOCX)
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